Selected ongoing studies using checkpoint blockade immunotherapy in treatment of recurrent or metastatic cervical cancer
| NCT identifier | Title | Phase | Planned enrollment | Primary endpoint(s) |
| NCT03257267 | Study of Cemiplimab in Adults With Cervical Cancer | III | 590 | Overall survival |
| NCT03912415 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) | III | 316 | Overall survival |
| NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) | III | 404 | Overall survival |
| NCT03192059 | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO) | II | 43 | Objective response rate |
| NCT03614949 | SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer | II | 26 | Overall response rate |
| NCT01693783 | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | II | 44 | Adverse events, objective response rate |
| NCT03277482 | Durvalumab, Tremelimumab+Radiotherapy in Gynecologic Cancer | I | 32 | Maximum tolerated dose |
| NCT03452332 | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers | I | 20 | Adverse events |